Illumina, Inc. (NASDAQ:ILMN) Director A Blaine Bowman sold 3,000 shares of the business’s stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $162.89, for a total transaction of $488,670.00. Following the transaction, the director now owns 18,704 shares in the company, valued at $3,046,694.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 162.57 on Friday. The firm’s 50-day moving average is $130.13 and its 200 day moving average is $150.44. The company has a market capitalization of $23.88 billion, a PE ratio of 54.55 and a beta of 1.16. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $186.88.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.10. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The company earned $607 million during the quarter, compared to the consensus estimate of $628.06 million. During the same quarter last year, the firm posted $0.80 EPS. The company’s quarterly revenue was up 10.4% on a year-over-year basis. On average, analysts anticipate that Illumina, Inc. will post $3.32 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright legislation. The original version of this article can be viewed at http://www.dailypolitical.com/2017/01/14/illumina-inc-ilmn-director-sells-488670-00-in-stock.html.

A number of brokerages recently issued reports on ILMN. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $141.42 price objective for the company. in a report on Tuesday, December 13th. Leerink Swann reiterated a “market perform” rating and issued a $132.00 price objective (up from $114.00) on shares of Illumina in a report on Wednesday. TheStreet cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Monday, December 5th. BTIG Research reiterated a “hold” rating on shares of Illumina in a report on Thursday, November 3rd. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $153.00 price objective (up from $147.00) on shares of Illumina in a report on Thursday. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $151.96.

Hedge funds have recently made changes to their positions in the company. Capital Research Global Investors increased its stake in shares of Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock valued at $1,836,882,000 after buying an additional 1,910,346 shares during the last quarter. Capital World Investors increased its stake in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock valued at $205,376,000 after buying an additional 1,003,000 shares during the last quarter. Baillie Gifford & Co. increased its stake in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock valued at $2,613,182,000 after buying an additional 682,010 shares during the last quarter. American Capital Management Inc. bought a new stake in shares of Illumina during the third quarter valued at approximately $43,373,000. Finally, Vanguard Group Inc. increased its stake in shares of Illumina by 2.0% in the second quarter. Vanguard Group Inc. now owns 8,982,784 shares of the life sciences company’s stock valued at $1,261,004,000 after buying an additional 178,186 shares during the last quarter. 92.94% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.